ASP 9603Alternative Names: ASP-9603
Latest Information Update: 12 Nov 2016
At a glance
- Originator Astellas Pharma
- Class Antineoplastics
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 13 May 2013 Discontinued - Phase-I for Prostate cancer in Japan (PO)
- 01 Feb 2012 Phase-I clinical trials in Prostate cancer in Japan (PO)